Trump Administration Plans to Speed FDA Approval of Vapes and Nicotine Pouches

Investing.com··US·Read original
3▲3 ▼0Impact / 5
Summary · why it matters

The Trump administration is preparing a major regulatory shift to accelerate market authorization for smoke-free nicotine products, according to reporting by The Wall Street Journal. The Food and Drug Administration is expected to announce changes in coming days that ease the requirements of its 2021 premarket review framework, establishing a streamlined pathway for alternative nicotine delivery systems, particularly flavored vapes and nicotine pouches. The overhaul aims to simplify scientific study standards and shorten review times for non-combustible alternatives, which under existing rules face years of regulatory backlog. A streamlined process would provide a substantial operational tailwind for major tobacco operators including Altria Group, Philip Morris International and British American Tobacco, and Altria's NJOY vape division recently joined other industry players in suing the FDA over regulatory delays. Administration officials view the proposed rules as a way to displace illicit, unregulated products dominating the domestic marketplace, but the shift faces pushback from public health advocates and bipartisan lawmakers who argue that expanding flavored product authorizations risks increasing youth adoption rates.

Impact on assets 4

Consumer Staples▲ · 3 stocks
Altria Group
MO
▲ PositiveRegulationrelevance

FDA streamlining premarket review would speed authorization of Altria's flavored vapes and NJOY nicotine pouches

British American Tobacco PLC
BATS
▲ PositiveRegulationrelevance

Streamlined FDA review of flavored vapes and nicotine pouches is a regulatory tailwind for British American Tobacco

Philip Morris International Inc
PM
▲ PositiveRegulationrelevance

Faster FDA authorization pathway for smoke-free nicotine products benefits Philip Morris International's alternatives portfolio

Cloud & Digital Infrastructure▲ · 1 stocks